In large clinical trials focused on individuals with type 2 diabetes mellitus (T2DM), SGLT2 inhibitors have been found to elevate hemoglobin and hematocrit levels, offering a potential remedy for anemia, a commonly encountered complication in patients with T2DM [19]. Here, SLC5A2 is linked to type 2 diabetes mellitus.